U.S. License Holder:
Sanofi Aventis US
Date of License:
August-03-2012
Last Update:
Nov-15-2023
FDA-Approved Indications
ZALTRAP (ziv-aflibercept), a vascular endothelial growth factor inhibitor, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.